SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Yarkadas Hayati
(Last) (First) (Middle)
C/O XYLEM INC.
301 WATER ST SE
(Street)
WASHINGTON DC 20003
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Xylem Inc. [ XYL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP & President, EU, WI & GLS
3. Date of Earliest Transaction (Month/Day/Year)
03/01/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/01/2024 A 7,084(1) A $127.94 19,198(2) D
Common Stock 03/01/2024 F 428(3) D $127.94 18,770 D
Common Stock 03/01/2024 M 9,698 A $102.23 28,468 D
Common Stock 03/01/2024 S 9,698 D $127.14(4) 18,770 D
Common Stock 03/01/2024 M 5,035 A $86.76 23,805 D
Common Stock 03/01/2024 S 5,035 D $127.14(4) 18,770 D
Common Stock 03/01/2024 S 4,870 D $127.14(4) 13,900 D
Common Stock 03/01/2024 M 4,875 A $101.09 18,775 D
Common Stock 03/01/2024 S 4,875 D $127.17(4) 13,900 D
Common Stock 03/05/2024 S 4,547 D $127.53(5) 9,353 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy) $102.23 03/01/2024 M 9,698 (6) 03/01/2031 Common Stock 9,698 $0.00 0.00 D
Non-Qualified Stock Option (Right to Buy) $101.09 03/01/2024 M 4,875 (7) 03/01/2033 Common Stock 4,875 $0.00 9,750 D
Non-Qualified Stock Option (Right to Buy) $86.76 03/01/2024 M 5,035 (8) 03/01/2032 Common Stock 5,035 $0.00 5,036 D
Stock Options (Right to buy) $127.94 03/01/2024 A 7,932 (9) 03/01/2034 Common Stock 7,932 $127.94 7,932 D
Explanation of Responses:
1. Reflects the acquisition of 4,739 shares of common stock upon vesting of performance-based stock units granted on March 1, 2021 under the Xylem Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to ROIC (2,934) and Total Shareholder Return (1,805). Reflects an award of 2,345 restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24, 2016) that are scheduled to vest in one third increments on March 1, 2025, March 1, 2026 and March 1, 2027.
2. Includes additional shares due to dividend reinvestment.
3. Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of performance-based stock units granted on March 1, 2021 (252) under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24, 2016). Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of restricted stock units granted on March 1, 2021 (39), March 1, 2022 (62), and March 1, 2023 (75) under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016).
4. This price represents the weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"). These Shares were executed at a range of prices from $127.03 to $127.30. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price.
5. This price represents the weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"). These Shares were executed at a range of prices from $127.10 to $127.55. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price.
6. The March 1, 2021 option grant vested 3,201 options on March 1, 2022, 3,265 options on March 1,2023, and 3,232 options on March 1, 2024.
7. The March 1, 2023 option grant vested 4,875 options on March 1, 2024, and will vest 4,875 options on March 1, 2025, and 4,875 options on March 1, 2026.
8. The March 1, 2022 option grant vested 5,035 options on March 1, 2023, 5,035 options on March 1, 2024, and will vest 5,036 options on March 1, 2025.
9. Reflects an award of non-qualified stock options pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one-third increments on March 1, 2025, March 1, 2026 and March 1, 2027.
Remarks:
/s/ Seaneen Cline, by power of attorney for Hayati Yarkadas 03/05/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Xylem (NYSE:XYL)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Xylem Charts.
Xylem (NYSE:XYL)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Xylem Charts.